Researchers at the University of Cambridge have conducted the first human trial of a vaccine component created entirely by artificial intelligence.
The vaccine features an AI-designed “super-antigen” aimed at training the immune system to respond to a wide range of coronaviruses. This approach does not focus on a single virus strain; instead, AI processed genetic material from multiple coronaviruses to design an antigen targeting the broader virus family, including current Covid variants and animal-origin coronaviruses with pandemic potential.
The initial trial included 39 participants and
The vaccine features an AI-designed “super-antigen” aimed at training the immune system to respond to a wide range of coronaviruses. This approach does not focus on a single virus strain; instead, AI processed genetic material from multiple coronaviruses to design an antigen targeting the broader virus family, including current Covid variants and animal-origin coronaviruses with pandemic potential.
The initial trial included 39 participants and